메뉴 건너뛰기




Volumn 49, Issue 2 A, 2003, Pages 62-65

The design of clinical trials in psoriasis: Lessons for clinical practice

Author keywords

[No Author keywords available]

Indexed keywords

CICLOPIROXOLAMINE; NEW DRUG;

EID: 0042634226     PISSN: 01909622     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review
Times cited : (12)

References (8)
  • 1
    • 0035462130 scopus 로고    scopus 로고
    • From idea to market: The drug approval process
    • Lipsky MS, Sharp LK. From idea to market: the drug approval process. J Am Board Fam Pract 2001;14:362-7.
    • (2001) J Am Board Fam Pract , vol.14 , pp. 362-367
    • Lipsky, M.S.1    Sharp, L.K.2
  • 2
    • 0034003425 scopus 로고    scopus 로고
    • The roles of the pharmaceutical industry and drug development in dermatology and dermatologic health care
    • Altman DJ. The roles of the pharmaceutical industry and drug development in dermatology and dermatologic health care. Dermatol Clin 2000;18:287-96.
    • (2000) Dermatol Clin , vol.18 , pp. 287-296
    • Altman, D.J.1
  • 4
    • 0032832339 scopus 로고    scopus 로고
    • Acitretin in combination with UVB or PUVA
    • Lebwohl M. Acitretin in combination with UVB or PUVA. J Am Acad Dermatol 1999;41:S22-S24.
    • (1999) J Am Acad Dermatol , vol.41
    • Lebwohl, M.1
  • 5
    • 0018099294 scopus 로고
    • Severe psoriasis - Oral therapy with a new retinoid
    • Fredriksson T, Pettersson U. Severe psoriasis - oral therapy with a new retinoid. Dermatologica 1978;157:238-44.
    • (1978) Dermatologica , vol.157 , pp. 238-244
    • Fredriksson, T.1    Pettersson, U.2
  • 6
    • 0033854994 scopus 로고    scopus 로고
    • Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis?
    • Krueger GG, Feldman SR, Camisa C, Duvic M, Elder JT, Gottlieb AB, et al. Two considerations for patients with psoriasis and their clinicians: What defines mild, moderate, and severe psoriasis? What constitutes a clinically significant improvement when treating psoriasis? J Am Acad Dermatol 2000;43:281-5.
    • (2000) J Am Acad Dermatol , vol.43 , pp. 281-285
    • Krueger, G.G.1    Feldman, S.R.2    Camisa, C.3    Duvic, M.4    Elder, J.T.5    Gottlieb, A.B.6
  • 7
    • 0041584947 scopus 로고    scopus 로고
    • Penlac. Penlac product information. Available at: http://www. fda.gov/cder/foi/label/1999/21022bl.pdf. Accessed July 27, 2002.
    • (2002) Penlac Product Information
  • 8
    • 0041584950 scopus 로고    scopus 로고
    • National Psoriasis Foundation. Available at: www.psoriasis.org. Accessed July 27, 2002.


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.